Scarica l'app Stockscreener
1.94
9.60%
0.17
Precedente Chiudi:
$1.77
Aprire:
$1.8
Volume 24 ore:
2.27M
Relative Volume:
1.38
Capitalizzazione di mercato:
$169.57M
Reddito:
$2.24M
Utile/perdita netta:
$-136.67M
Rapporto P/E:
-0.8472
EPS:
-2.29
Flusso di cassa netto:
$-102.08M
1 W Prestazione:
+94.99%
1M Prestazione:
+227.87%
6M Prestazione:
+210.05%
1 anno Prestazione:
+81.31%
Intervallo 1D:
$1.74
$1.95
Intervallo di 1 settimana:
$0.8975
$1.95
Portata 52W:
$0.3418
$1.95
Century Therapeutics Inc Stock (IPSC) Company Profile
Nome
Century Therapeutics Inc
Settore
Industria
Telefono
215-981-4000
Indirizzo
25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA
Confronta IPSC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IPSC
Century Therapeutics Inc
|
1.94 | 154.71M | 2.24M | -136.67M | -102.08M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Century Therapeutics Inc Stock (IPSC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-08 | Iniziato | Rodman & Renshaw | Buy |
| 2023-08-28 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-12-27 | Iniziato | Chardan Capital Markets | Buy |
| 2022-10-31 | Iniziato | Guggenheim | Buy |
| 2022-10-10 | Iniziato | Canaccord Genuity | Buy |
| 2022-05-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-12 | Iniziato | William Blair | Mkt Perform |
| 2021-07-13 | Iniziato | BofA Securities | Buy |
| 2021-07-13 | Iniziato | JP Morgan | Overweight |
| 2021-07-13 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics (NASDAQ:IPSC) Upgraded at Zacks Research - Defense World
Is Century Therapeutics Inc. stock supported by strong cash flowsWeekly Trading Summary & Free Technical Pattern Based Buy Signals - ulpravda.ru
Can Century Therapeutics Inc. stock outperform in 2025 bull marketMarket Performance Summary & Expert Verified Stock Movement Alerts - ulpravda.ru
Century Therapeutics Inc. (IPSC) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Can Century Therapeutics Inc. stock surprise with earnings upsidePortfolio Return Summary & AI Forecasted Stock Moves - ulpravda.ru
Century Therapeutics Inc.: Is an Upswing Approaching? - StocksToTrade
Century Therapeutics wins $135M private placement (IPSC:NASDAQ) - Seeking Alpha
Will Century Therapeutics Inc. stock deliver better than expected guidanceEarnings Growth Summary & Trade Opportunity Analysis Reports - ulpravda.ru
Century Therapeutics stock price target lowered to $6.60 at Clear Street - Investing.com Canada
Is Century Therapeutics Inc. stock attractive after correctionJuly 2025 PreEarnings & Consistent Growth Stock Picks - ulpravda.ru
Aug Swings: What sentiment indicators say about Century Therapeutics Inc. stockTrend Reversal & Daily Chart Pattern Signals - ulpravda.ru
Why Century Therapeutics Inc. stock is rated strong buyTrade Entry Report & Weekly Market Pulse Updates - ulpravda.ru
Will Century Therapeutics Inc. stock deliver long term returnsAnalyst Downgrade & Long Hold Capital Preservation Plans - ulpravda.ru
Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes - Investing News Network
Century Therapeutics: New Leadership Sparks Interest - timothysykes.com
Layoff Watch: Is Century Therapeutics Inc. stock attractive for income investors2025 Risk Factors & Verified Short-Term Plans - ulpravda.ru
Century Therapeutics secures $135 million in private placement By Investing.com - Investing.com India
Century Therapeutics secures oversubscribed $135 million private placement financing to support lead program, CNTY-813 - MarketScreener
Century Therapeutics Signs Multiple Financing Agreements - TradingView — Track All Markets
Big bet on type 1 diabetes: $135M backs potentially curative cell therapy - Stock Titan
Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain - Yahoo Finance
Century Therapeutics (IPSC) price target decreased by 20.00% to 4.08 - MSN
Critical Analysis: EOM Pharmaceutical (OTCMKTS:IMUC) & Century Therapeutics (NASDAQ:IPSC) - Defense World
Trend Report: Is Century Therapeutics Inc stock attractive after correctionJuly 2025 Update & Expert-Curated Trade Recommendations - moha.gov.vn
Street Watch: Why Century Therapeutics Inc stock is rated strong buyJuly 2025 Macro Moves & Safe Entry Trade Reports - moha.gov.vn
Chad Cowan Buys 58,060 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics announces resignation of board member - TipRanks
Century Therapeutics Announces Board Resignation - TradingView — Track All Markets
Century Therapeutics, Inc. Announces Resignation of Carlo Rizzuto as Director., Effective December 18, 2025 - marketscreener.com
Century Therapeutics (IPSC) announces board resignation of Carlo Rizzuto - Stock Titan
Century Therapeutics Unveils iPSC Beta Islet Program as Cash Runway Extends Into 2027 - MSN
Century Therapeutics, Inc. (NASDAQ:IPSC) Sees Significant Decrease in Short Interest - MarketBeat
Century Therapeutics to Showcase Promising Cell Therapy Data at ASGCT Annual Meeting - MSN
What sentiment indicators say about Century Therapeutics Inc. stockJuly 2025 Review & Fast Entry Momentum Alerts - DonanımHaber
Will Century Therapeutics Inc. stock benefit from infrastructure spendingStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Can Century Therapeutics Inc. stock reach $100 price targetMarket Performance Recap & Expert Curated Trade Ideas - DonanımHaber
Century Therapeutics adds veteran deal-makers to board as pipeline nears clinic - MSN
Why Century Therapeutics Inc. stock is popular among millennialsRisk Management & Target Return Focused Stock Picks - DonanımHaber
There's No Escaping Century Therapeutics, Inc.'s (NASDAQ:IPSC) Muted Revenues Despite A 32% Share Price Rise - simplywall.st
Brent Pfeiffenberger Purchases 52,000 Shares of Century Therapeutics (NASDAQ:IPSC) Stock - MarketBeat
Century Therapeutics CEO Brent Pfeiffenberger Acquires 52,000 Shares - TradingView — Track All Markets
Century Therapeutics (IPSC) CEO and director reports 52,000-share buy - Stock Titan
Century Therapeutics Adds Veteran Deal-Makers to Board as Pipeline Nears Clinic - MyChesCo
Century Therapeutics (NASDAQ:IPSC) Trading Up 2.5% – Still a Buy? - Defense World
Century Therapeutics Earnings Notes - Trefis
[Form 4] Century Therapeutics, Inc. Insider Trading Activity - Stock Titan
Century Therapeutics, Inc. Updates on Cell Therapy Developments - TradingView — Track All Markets
IPS Cell-Derived Platelets Market to Rise at 9.6% CAGR Through 2025-2031: Industry and Companies Analysis Featuring Megakaryon, Xueji Shengwu, Renerval, Help, Cynata, Fate, and Century TherapeuticsResearchAndMarkets.com - Markets Financial Content
Century Therapeutics’ Long-Term Follow-Up Study: Key Insights for Investors - MSN
Century Therapeutics : Initial Statement of Beneficial Ownership (Form 3) - marketscreener.com
Century Therapeutics director reports zero beneficial share ownership | IPSC SEC FilingForm 3 - Stock Titan
Century Therapeutics Inc Azioni (IPSC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.90%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):